A Phase II Study of Sitravatinib Combined With Tislelizumab Plus Docetaxel for Acquired Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Abstract

Trial registration: Chictr.org.cn, ChiCTR2200065547. Registered in 2022-11-08, https://www.chictr.org.cn/showproj.html?proj=183439.

Keywords

acquired resistance / CD4⁺ T cell / immunotherapy / single-cell secretome proteomics / TCR sequencing

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[2] K. Xu, H. Wang, S. Li, et al., “Changing Profile of Lung Cancer Clinical Characteristics in China: Over 8-Year Population-Based Study,” Chinese Medical Journal Pulmonary and Critical Care Medicine 1, no. 3 (2023): 188–194.

[3] A. H. Sharpe and K. E. Pauken, “The Diverse Functions of the PD1 Inhibitory Pathway,” Nature Reviews Immunology 18, no. 3 (2018): 153–167.

[4] W. Luo, Z. Wang, T. Zhang, et al., “Immunotherapy in Non-Small Cell Lung Cancer: Rationale, Recent Advances and Future Perspectives,” Precision Clinical Medicine 4, no. 4 (2021): 258–270.

[5] Y. Xu, Y. Liu, Y. Ge, H. Li, Y. Zhang, and L. Wang, “Drug Resistance Mechanism and Reversal Strategy in Lung Cancer Immunotherapy,” Frontiers in Pharmacology 14 (2023): 1230824.

[6] Z. He, C. Zhang, M. Ran, et al., “The Modified Lymphocyte C-Reactive Protein Score Is a Promising Indicator for Predicting 3-Year Mortality in Elderly Patients With Intertrochanteric Fractures,” BMC Geriatr 23, no. 1 (2023): 432.

[7] L. Berland, Z. Gabr, M. Chang, et al., “Further Knowledge and Developments in Resistance Mechanisms to Immune Checkpoint Inhibitors,” Frontiers in Immunology 15 (2024): 1384121.

[8] L. P. Zhao, J. H. Hu, D. Hu, et al., “Hyperprogression, a Challenge of PD-1/PD-L1 Inhibitors Treatments: Potential Mechanisms and Coping Strategies,” Biomedicine & Pharmacotherapy 150 (2022): 112949.

[9] S. J. Antonia, H. Borghaei, S. S. Ramalingam, et al., “Four-year Survival With nivolumab in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Pooled Analysis,” The Lancet Oncology 20, no. 10 (2019): 1395–1408.

[10] K. E. de Visser and J. A. Joyce, “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell 41, no. 3 (2023): 374–403.

[11] L. Wang, Q. Jia, Q. Chu, and B. Zhu, “Targeting Tumor Microenvironment for Non-Small Cell Lung Cancer Immunotherapy,” Chinese Medical Journal: Pulmonary and Critical Care Medicine 1, no. 1 (2023): 18–29.

[12] B. Wang, Y. Han, Y. Zhang, et al., “Overcoming Acquired Resistance to Cancer Immune Checkpoint Therapy: Potential Strategies Based on Molecular Mechanisms,” Cell & Bioscience 13, no. 1 (2023): 120.

[13] A. J. Schoenfeld and M. D. Hellmann, “Acquired Resistance to Immune Checkpoint Inhibitors,” Cancer Cell 37, no. 4 (2020): 443–455.

[14] W. Du, H. Huang, N. Sorrelle, and R. A. Brekken, “Sitravatinib Potentiates Immune Checkpoint Blockade in Refractory Cancer Models,” JCI Insight 3, no. 21 (2018).

[15] R. Sweeney, A. N. Omstead, J. T. Fitzpatrick, et al., “Sitravatinib Combined With PD-1 Blockade Enhances Cytotoxic T-Cell Infiltration by M2 to M1 Tumor Macrophage Repolarization in Esophageal Adenocarcinoma,” Carcinogenesis 45, no. 4 (2024): 210–219.

[16] J. Zhao, X. Yu, D. Huang, et al., “SAFFRON-103: A Phase 1b Study of the Safety and Efficacy of Sitravatinib Combined With tislelizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,” Journal for ImmunoTherapy of Cancer 11, no. 2 (2023).

[17] X. Wang, H. Pan, J. Cui, et al., “SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma,” Immunotherapy 16, no. 4 (2024): 243–256.

[18] J. Zhang, Y. Wang, Y. Huang, et al., “Characterization of T Cell Receptor Repertoire in Penile Cancer,” Cancer Immunology, Immunotherapy 73, no. 2 (2024): 24.

[19] K. He, D. Berz, S. M. Gadgeel, et al., “MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients with Nonsquamous NSCLC Progressing on or After Checkpoint Inhibitor Therapy or Chemotherapy,” Journal of Thoracic Oncology 18, no. 7 (2023): 907–921.

[20] I. A. Jaiyesimi, N. B. Leighl, N. Ismaila, et al., “Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3,” Journal of Clinical Oncology 42, no. 11 (2024): e23–e43.

[21] H. Borghaei, F. de Marinis, D. Dumoulin, et al., “SAPPHIRE: Phase III Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer,” Annals of Oncology 35, no. 1 (2024): 66–76.

[22] K. Wang, Z. Fu, G. Sun, et al., “Systemic Treatment Options for Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis Based on Randomized Controlled Trials,” BMC Immunology [Electronic Resource] 25, no. 1 (2024): 37.

[23] N. Saijo, “The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology,” Yonsei Medical Journal 54, no. 1 (2013): 1–14.

[24] Q. Zhou, B. Gao, J. Hu, et al., “OA06.03 SAFFRON-301: Tislelizumab plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/After Chemotherapy and Anti-PD-(L)1,” Journal of Thoracic Oncology 19, no. 10 (2024): S19–S20.

[25] J. Yang, J. Zhou, and S. Mackay, “Abstract LB094: First of Its Kind T Cell Receptors and Functional Proteomics Detected From the Same Single Cells to Advance Cancer Immunology Discovery,” Cancer Research 82, no. 12 (2022): LB094–LB094.

[26] A. Kjær, N. Kristjánsdóttir, R. I. Juul, et al., “Low T Cell Diversity Associates With Poor Outcome in Bladder Cancer: A Comprehensive Longitudinal Analysis of the T Cell Receptor Repertoire,” Cell Reports Medicine 6, no. 5 (2025): 102101.

[27] A. Reuben, J. Zhang, S. H. Chiou, et al., “Comprehensive T Cell Repertoire Characterization of Non-small Cell Lung Cancer,” Nature Communications 11, no. 1 (2020): 603.

[28] M. Tichet, S. Wullschleger, A. Chryplewicz, et al., “Bispecific PD1-IL2v and Anti-PD-L1 Break Tumor Immunity Resistance by Enhancing Stem-Like Tumor-Reactive CD8(+) T Cells and Reprogramming Macrophages,” Immunity 56, no. 1 (2023): 162–179. e166.

[29] M. Oliva, D. Chepeha, D. V. Araujo, et al., “Antitumor Immune Effects of Preoperative Sitravatinib and Nivolumab in Oral Cavity Cancer: SNOW Window-of-Opportunity Study,” Journal for ImmunoTherapy of Cancer 9, no. 10 (2021): e003476.

[30] S. Peters, L. Paz-Ares, R. S. Herbst, and M. Reck, “Addressing CPI Resistance in NSCLC: Targeting TAM Receptors to Modulate the Tumor Microenvironment and Future Prospects,” Journal for ImmunoTherapy of Cancer 10, no. 7 (2022): e004863.

[31] Z. C. Ding, H. Shi, N. S. Aboelella, et al., “Persistent STAT5 Activation Reprograms the Epigenetic Landscape in CD4(+) T Cells to Drive Polyfunctionality and Antitumor Immunity,” Science Immunology 5, no. 52 (2020): eaba5962.

[32] B. Duchemann, M. Naigeon, E. Auclin, et al., “CD8(+)PD-1(+) to CD4(+)PD-1(+) Ratio (PERLS) Is Associated With Prognosis of Patients With Advanced NSCLC Treated With PD-(L)1 Blockers,” Journal for ImmunoTherapy of Cancer 10, no. 2 (2022): e004012.

[33] Z. F. Lim, X. Wu, L. Zhu, et al., “Quantitative Peripheral Live Single T-Cell Dynamic Polyfunctionality Profiling Predicts Lung Cancer Checkpoint Immunotherapy Treatment Response and Clinical Outcomes,” Translational Lung Cancer Research 13, no. 12 (2024): 3323–3343.

[34] D. Y. Oh, S. S. Kwek, S. S. Raju, et al., “Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer,” Cell 181, no. 7 (2020): 1612–1625. e1613.

[35] J. M. González-Navajas, E. Elkord, and J. Lee, “Editorial: CD4(+) T Cells in Cancer Immunotherapies,” Frontiers in Immunology 12 (2021): 737615.

[36] M. Reck, N. Frost, S. Peters, et al., “Treatment of NSCLC After Chemoimmunotherapy—Are We Making Headway?,” Nature Reviews Clinical Oncology 22, no. 11 (2025): 806–830.

[37] F. Zhang, H. Bai, R. Gao, et al., “Dynamics of Peripheral T Cell Clones During PD-1 Blockade in Non-Small Cell Lung Cancer,” Cancer Immunology, Immunotherapy 69, no. 12 (2020): 2599–2611.

[38] F. Skoulidis, H. A. Araujo, M. T. Do, et al., “CTLA4 blockade Abrogates KEAP1/STK11-Related Resistance to PD-(L)1 Inhibitors,” Nature 635, no. 8038 (2024): 462–471.

[39] E. Alspach, D. M. Lussier, A. P. Miceli, et al., “MHC-II Neoantigens Shape Tumour Immunity and Response to Immunotherapy,” Nature 574, no. 7780 (2019): 696–701.

[40] H. Kagamu, S. Kitano, O. Yamaguchi, et al., “CD4(+) T-cell Immunity in the Peripheral Blood Correlates With Response to Anti-PD-1 Therapy,” Cancer Immunology Research 8, no. 3 (2020): 334–344.

[41] J. L. Root, P. N. Desai, C. Ly, et al., “Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy,” Cancer Research Communications 4, no. 3 (2024): 671–681.

[42] Q. Peng, Y. Xu, and X. Yao, “scRNA+ TCR-seq Revealed Dual TCR T Cells Antitumor Response in the TME of NSCLC,” Journal for ImmunoTherapy of Cancer 12, no. 9 (2024): e009376.

[43] D. A. Bolotin, S. Poslavsky, I. Mitrophanov, et al., “MiXCR: Software for Comprehensive Adaptive Immunity Profiling,” Nature Methods 12, no. 5 (2015): 380–381.

[44] N. Bowman, D. Liu, P. Paczkowski, et al., “Advanced Cell Mapping Visualizations for Single Cell Functional Proteomics Enabling Patient Stratification,” Proteomics 20, no. 13 (2020): e1900270.

[45] J. Rossi, P. Paczkowski, Y. W. Shen, et al., “Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With Clinical Outcomes in NHL,” Blood 132, no. 8 (2018): 804–814.

[46] A. Diab, S. S. Tykodi, G. A. Daniels, et al., “Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma,” Journal of Clinical Oncology 39, no. 26 (2021): 2914–2925.

[47] R. Brookmeyer and J. Crowley, “A Confidence Interval for the Median Survival Time,” Biometrics 38, no. 1 (1982): 29–41.

[48] M. Greenwood, A Report on the Natural Duration of Cancer (London: H.M.S.O. 1926), iv + 26.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.